306 related articles for article (PubMed ID: 3052079)
1. Prospective study of carbohydrate metabolism in women using a triphasic oral contraceptive containing norethindrone and ethinyl estradiol for 3 months.
Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
Am J Obstet Gynecol; 1988 Oct; 159(4):877-9. PubMed ID: 3052079
[TBL] [Abstract][Full Text] [Related]
2. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
3. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
4. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives.
Kojima T; Lindheim SR; Duffy DM; Vijod MA; Stanczyk FZ; Lobo RA
Am J Obstet Gynecol; 1993 Dec; 169(6):1540-4. PubMed ID: 8267059
[TBL] [Abstract][Full Text] [Related]
5. Lack of metabolic effects of a triphasic formulation containing norethindrone in normal women studied prospectively.
Toth EL; Ryan EA
Contraception; 1988 Jun; 37(6):549-54. PubMed ID: 3293908
[TBL] [Abstract][Full Text] [Related]
6. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D; Smith S; Zacur H
Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
8. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
[TBL] [Abstract][Full Text] [Related]
9. Glucose and insulin levels after six months of treatment with a triphasic oral contraceptive containing ethinyl estradiol and norethindrone.
Spellacy WN; Ellingson AB; Tsibris JC
J Reprod Med; 1989 Aug; 34(8):540-2. PubMed ID: 2681750
[TBL] [Abstract][Full Text] [Related]
10. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.
Spellacy WN; Ellingson AB; Tsibris JC
Fertil Steril; 1989 Jan; 51(1):71-4. PubMed ID: 2642814
[TBL] [Abstract][Full Text] [Related]
11. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate metabolism studies in women using Brevicon, a low-estrogen type of oral contraceptive, for one year.
Spellacy WN; Buhi WC; Birk SA; Van Arnarn JB
Am J Obstet Gynecol; 1982 Jan; 142(1):105-8. PubMed ID: 7034537
[TBL] [Abstract][Full Text] [Related]
13. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive.
Ling WY; Johnston DW; Lea RH; Bent AE; Scott JZ; Toews MR
Contraception; 1985 Oct; 32(4):367-75. PubMed ID: 3935373
[TBL] [Abstract][Full Text] [Related]
14. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
Masson S; Franssen E; Hilditch JR; Powell MG
Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001
[TBL] [Abstract][Full Text] [Related]
15. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
Rosenfeld WE; Doose DR; Walker SA; Nayak RK
Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
17. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
Spellacy WN
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
[TBL] [Abstract][Full Text] [Related]
18. Contraception for women with diabetes: an update.
Skouby SO; Mølsted-Pedersen L; Petersen KR
Baillieres Clin Obstet Gynaecol; 1991 Jun; 5(2):493-503. PubMed ID: 1954724
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
20. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
Spellacy WN; Tsibris JC; Hunter-Bonner DL; Smalling S; Chez RA; Angel JL; O'Brien WF
Contraception; 1992 Jun; 45(6):533-9. PubMed ID: 1617962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
